Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

Edwards Lifesciences Corp (EW)

As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data

Report price $107.11 (close 2026-11-16); latest close $101.85 (2026-11-20), -4.9% since the report; figures re-marked at the latest close

Conclusion: WATCH

Conviction low · base case -46% · downside -54% · upside +13%

The market is pricing Edwards as a durable compounder: at $107.11 the $57.54B enterprise value is 8.62x TTM sales of $6.67B and 39.9x TTM EBIT, while the reverse DCF needs only +6.1% revenue growth a year for ten years against +11.5% delivered in the latest fiscal year. That durability claim is why the call is WATCH rather than a directional bet: the franchise earns a 14.4% ROIC against a 6.3% WACC and holds $4.05B net cash, but the price already discounts it. The base case is $54.52, -49.1%, on EV/Sales at 4.09x, the peer median EV/Sales. The downside is $46.34, -56.7%, on the base case's multiple on -15.0% earnings. The upside is $115.12, +7.5%, on +8% sales at today's EV/Sales of 8.62x. The asymmetry is unfavorable, and the peer anchor rests on only three comparables, so conviction is low.

Key numbers

  • Share price: $101.85
  • Market cap: $58.56B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $6.67B
  • EV / EBITDA (TTM): 33.8x
  • P/E (TTM): 57.3x
  • FCF yield: 2.4%
  • Price / book: 5.39x
  • Earnings-quality flags (TTM): Impairments -$367.1M (36% of net income)
  • P/E, adjusted (TTM): 42.2x
  • EV / FCF (TTM): 38.3x
  • Revenue growth (latest fiscal year): +11.5%
  • ROIC (TTM): 14.4%
  • WACC: 6.3%
  • Economic profit spread: +8.0 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Edwards Lifesciences sells implantable heart-valve devices, not services: in the FY2025 10-K the business is three product groups — TAVR, TMTT and Surgical Structural Heart — with TAVR at 74% of net sales in 2025, TMTT at 9% and surgical tissue valves at 17%. The FY2020 10-K on file described a fourth group, Critical Care (9% of 2020 net sales), which no longer appears among the product groups in the FY2025 description, so the company is now a pure structural-heart story with TAVR as the revenue engine. Revenue rose from $4.39B in FY2020 to $6.07B in FY2025 and $6.67B TTM to 30 Sep 2026, but operating income has not kept pace — $1.26B in FY2025 and $1.44B TTM against gross profit of $4.73B and $5.21B — and the reported FY2024 net income of $4.17B sits far above that year's $1.55B pre-tax income, so it is not a measure of operating profitability. Cash conversion is the stronger number: operating cash flow of $1.60B in FY2025 and $1.72B TTM to 30 Sep 2026 against capex of $260.2M and $292.8M.

  2. ✓ 2. Competitive advantage

    The sources support a procedure-driven franchise advantage, not a quantifiable wide moat: EW is a leading global competitor in each product line with recognizable structural-heart brands and field clinical support, but Medtronic and Abbott are named primary competitors across TAVR, TMTT and Surgical. Revenue and gross profit grew to $6.07B/$4.73B in FY2025 and $6.67B/$5.21B TTM to 2026-09-30, while operating income was $1.26B FY2025 and $1.44B TTM versus $1.69B FY2021. Cash generation is strong at $1.60B operating cash flow FY2025 and $1.72B TTM, but the sources give no market-share, retention or switching-cost numbers.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 sales were $1,715.5 million, up 10.5% from Q3 2025 (11.2% constant currency), led by TMTT +44.3% and TAVR +8.0%; gross margin was 78.5% and adjusted operating margin 30.3%. Management raised FY2026 sales growth guidance to about 11.5%, TMTT sales to $780-$790 million, and adjusted EPS to $2.97-$3.05. Cash was about $3.1 billion with about $600 million of debt, and nine-month buybacks were $696.6 million. One-offs are material: a $174.4 million tax valuation allowance and $220.2 million of impairment charges sit apart from $0.801 adjusted EPS.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans